• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by CRISPR Therapeutics AG

    11/14/25 12:26:20 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRSP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CRISPR Therapeutics AG

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    H17182108

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    H17182108


    1Names of Reporting Persons

    ORBIS INVESTMENT MANAGEMENT LTD
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,974,125.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,974,125.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,974,125.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    H17182108


    1Names of Reporting Persons

    Allan Gray Australia Pty Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    AUSTRALIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,960.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,960.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,960.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CRISPR Therapeutics AG
    (b)Address of issuer's principal executive offices:

    BAARERSTRASSE 14, ZUG, SWITZERLAND 6300
    Item 2. 
    (a)Name of person filing:

    ORBIS INVESTMENT MANAGEMENT LTD Allan Gray Australia Pty Ltd
    (b)Address or principal business office or, if none, residence:

    ORBIS INVESTMENT MANAGEMENT LTD: Orbis House, 25 Front Street, Hamilton, Bermuda HM11 Allan Gray Australia Pty Ltd: Level 2, Challis House, 4 Martin Place, Sydney NSW2000, Australia
    (c)Citizenship:

    ORBIS INVESTMENT MANAGEMENT LTD - BERMUDA Allan Gray Australia Pty Ltd - AUSTRALIA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    H17182108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Equivalent to IA.
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,982,085
    (b)Percent of class:

    5.5  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    ORBIS INVESTMENT MANAGEMENT LTD - 4,974,125 Allan Gray Australia Pty Ltd - 7,960

     (ii) Shared power to vote or to direct the vote:

    ORBIS INVESTMENT MANAGEMENT LTD - 0 Allan Gray Australia Pty Ltd - 0

     (iii) Sole power to dispose or to direct the disposition of:

    ORBIS INVESTMENT MANAGEMENT LTD - 4,974,125 Allan Gray Australia Pty Ltd - 7,960

     (iv) Shared power to dispose or to direct the disposition of:

    ORBIS INVESTMENT MANAGEMENT LTD - 0 Allan Gray Australia Pty Ltd - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Other persons have the right to receive dividends from, the power to direct the receipt of dividends from, or the right to receive the proceeds from the sale of, the securities of the issuer identified in Item 4(a) that are beneficially owned by Orbis Investment Management Ltd. Another person has the right to receive dividends from, the power to direct the receipt of dividends from, or the right to receive the proceeds from the sale of, the securities of the issuer identified in Item 4(a) that are beneficially owned by Allan Gray Australia Pty Ltd.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Information with respect to each of Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd (collectively, the "Reporting Persons") is given solely by each such Reporting Person and no Reporting Person has responsibility for the accuracy or completeness of information supplied by any other Reporting Person. Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd are classified as a Non-U.S. Institution (FI) that is equivalent to an Investment Adviser (IA). Notwithstanding that the Reporting Persons are making this filing together, none of the Reporting Persons represents that it is a member of a group for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. Each Reporting Person disclaims beneficial ownership of any shares beneficially owned by any other Reporting Person as specified in Item 4(a).
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ORBIS INVESTMENT MANAGEMENT LTD
     
    Signature:Matthew Gaarder
    Name/Title:Attorney-in-Fact
    Date:11/14/2025
     
    Allan Gray Australia Pty Ltd
     
    Signature:Matthew Gaarder
    Name/Title:Attorney-in-Fact
    Date:11/14/2025
    Exhibit Information

    POWER OF ATTORNEY THIS DEED OF POWER OF ATTORNEY is made on this the 6 day of June 2019. The undersigned, Orbis Investment Management Limited, a limited company duly organized under the laws of Bermuda with its registered office at Orbis House, 25 Front Street, Hamilton, HMI 1, Bermuda the "Company"), does hereby make, constitute and appoint each of Ali Ziai, David Gasperow, Elizabeth Lee, Eugene Tan, Hugh Gillespie, Ian Noetzel, James Dorr, Katharine Summerley, Matthew Gaarder, Michael Fox, Samantha Scott, and Tim Freeman acting severally, as its true and lawful attorneys-in-fact, for the purpose of from time to time executing in its name and on its behalf, whether the Company individually or as representative of others, any and all certificates, documents, filings, forms, instruments, schedules, statements, and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership and/or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including without limitation Forms 3, 4, 5, 13F, and 13H and Schedules 13D and 13G and any amendments to any of the foregoing as may be required to be filed with the U.S. Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates or subsidiaries. This power of attorney and any dispute or claim arising out of or in connection with it, its subject matter or its formation shall be governed by and construed in accordance with the law of Bermuda. IN WITNESS WHEREOF this power of attorney has been duly executed and delivered for and on behalf of the Company as a deed and takes effect on the date stated at the beginning of it. EXECUTED and DELIVERED as a DEED For and on behalf of ORBIS INVESTMENT MANAGEMENT LIMITED By: /s/ Matthew Furr Name: Matthew Furr Title: Director in the presence of: By: /s/ Daniel Samilski Witness signature Name: Daniel Samilski Address: Orbis House, 25 Front St, Hamilton HM 11, Bermuda Occupation: Compliance Manager POWER OF ATTORNEY This DEED OF POWER OF ATTORNEY is made on this the 6th day of June 2019. The undersigned, Allan Gray Australia Pty Limited, a proprietary company duly organized under the laws of Australia with its registered office at Level 2, Challis House, 4-10 Martin Place, Sydney NSW2000, Australia (the "Company"), does hereby make, constitute and appoint each of Ali Ziai, David Gasperow, Elizabeth Lee, Eugene Tan, Hugh Gillespie, Ian Noetzel, James Dorr, Katharine Summerley, Matthew Gaarder, Michael Fox, Samantha Scott, and Tim Freeman acting severally, as its true and lawful attorneys-in-fact, for the purpose of from time to time executing in its name and on its behalf, whether the Company individually or as representative of others, any and all certificates, documents, filings, fo1ms, instruments, schedules, statements, and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership and/or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including without limitation Fo1ms 3, 4, 5, 13F, and 13H and Schedules 13D and 13G and any amendments to any of the foregoing as may be required to be filed with the U.S. Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company, an affiliate or subsidiary of the Company, or an affiliate or subsidiary of Orbis Allan Gray Limited. This power of attorney and any dispute or claim arising out of or in connection with it, its subject matter or its formation shall be governed by and construed in accordance with the law of Australia. IN WITNESS WHEREOF this power of attorney has been duly executed and delivered for and on behalf of the Company as a deed and takes effect on the date stated at the beginning of it. EXECUTED and DELIVERED as a DEED For and on behalf of ALLAN GRAY AUSTRALIA PTY LIMITED By: /s/ Hugh Gillespie Name: Hugh Gillespie Title: Director in the presence of: By: /s/ Erika Mattatall Witness signature Name: Erika Mattatall Address: Orbis House, 25 Front St, Hamilton HM 11, Bermuda Occupation: Administrative Assistant

    Get the next $CRSP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRSP

    DatePrice TargetRatingAnalyst
    9/18/2025$70.00Overweight
    Analyst
    2/14/2025$60.00 → $99.00In-line → Outperform
    Evercore ISI
    2/12/2025$35.00Sell → Hold
    TD Cowen
    2/3/2025$65.00Buy
    H.C. Wainwright
    8/6/2024$88.00 → $84.00Buy
    Needham
    8/2/2024$90.00Buy
    Rodman & Renshaw
    6/28/2024Neutral
    Guggenheim
    2/15/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $CRSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Treco Douglas A bought $1,140,600 worth of shares (20,000 units at $57.03), increasing direct ownership by 1,000% to 22,000 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    8/8/25 4:06:28 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director George Simeon bought $51,499,918 worth of shares (989,812 units at $52.03) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    7/17/25 5:19:13 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Greene John bought $313,948 worth of shares (7,000 units at $44.85) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    2/28/25 5:35:05 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on CRISPR Therapeutics with a new price target

    Analyst initiated coverage of CRISPR Therapeutics with a rating of Overweight and set a new price target of $70.00

    9/18/25 8:39:47 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded CRISPR Therapeutics from In-line to Outperform and set a new price target of $99.00 from $60.00 previously

    2/14/25 8:06:15 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics upgraded by TD Cowen with a new price target

    TD Cowen upgraded CRISPR Therapeutics from Sell to Hold and set a new price target of $35.00

    2/12/25 7:01:19 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care

    Issued on behalf of Avant Technologies Inc. VANCOUVER, British Columbia, Nov. 19, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – The autologous cell therapy market surpassed $10.1 billion in 2025 as biotechnology companies race to commercialize therapies that read, replace, and rewrite cellular behavior to combat age-related diseases and metabolic disorders. The cell harvesting infrastructure expanded to support next-generation cell and gene therapy manufacturing, creating momentum across platforms from encapsulated cell delivery to gene-editing systems. Publicly traded companies positioned at the intersection of cell engineering, therapeutic protein delivery, and precision m

    11/19/25 10:06:39 AM ET
    $CRSP
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

    -Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine- -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), approximately 165 patients have completed their first cell collection and 39 have received infusions across all regions; Vertex expects clear line of sight to over $100 million in total CASGEVY revenue this year and significant growth expected in 2026- -Pediatric development of exa-cel is advancing in SCD and TDT, with enrollment in two global Phase 3 studies completed; initial

    11/10/25 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

    -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum -89%), a mean reduction in triglycerides (TG) of -55% (maximum -84%), and a mean reduction of low-density lipoprotein (LDL) of -49% (maximum -87%) at the highest dose- -Among participants with elevated baseline TG (>150 mg/dL), a mean reduction of 60% in TG were observed at therapeutic doses- -CTX310 was well tolerated with no treatment-related serious adverse events and no ≥Grade 3 changes in liver transaminases- -Findi

    11/8/25 9:56:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by CRISPR Therapeutics AG

    SCHEDULE 13G - CRISPR Therapeutics AG (0001674416) (Subject)

    11/14/25 12:26:20 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by CRISPR Therapeutics AG

    10-Q - CRISPR Therapeutics AG (0001674416) (Filer)

    11/10/25 8:15:47 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics AG filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CRISPR Therapeutics AG (0001674416) (Filer)

    11/10/25 8:10:33 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kulkarni Samarth converted options into 100,000 shares and sold $3,456,279 worth of shares (50,895 units at $67.91), increasing direct ownership by 24% to 254,201 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    10/20/25 5:35:03 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    General Counsel and Secretary Kasinger James R. converted options into 2,114 shares and sold $71,662 worth of shares (1,076 units at $66.60), increasing direct ownership by 1% to 83,402 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    10/15/25 5:35:03 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kulkarni Samarth converted options into 8,334 shares and sold $282,517 worth of shares (4,242 units at $66.60), increasing direct ownership by 2% to 205,096 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    10/15/25 5:35:05 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    4/10/24 11:58:51 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    2/12/24 6:22:35 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Leadership Updates

    Live Leadership Updates

    View All

    CRISPR Therapeutics Proposes New Appointment to the Board of Directors

    ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pip

    1/7/25 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

    -Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company al

    5/23/24 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics Announces Transition of Chief Financial Officer

    ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities. "I'm excited to welcome Raju to our leadership team," said Samarth Kulkarni, Ph.D., Chief Exec

    3/13/23 4:15:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Financials

    Live finance-specific insights

    View All

    CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

    -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion- -Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis- -Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)- -Expanding CARBON into a potentially registrational trial in 1Q 20

    10/12/21 4:01:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

    -Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. Conference Call and Web

    10/5/21 4:05:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care